(Reuters) – French drugmaker Sanofi said on Thursday it would restructure the U.S. commercial operations for its vaccines and cut an undisclosed number of jobs.
Sanofi would implement a “streamlined strategic sales structure” to better support its customers and patients, it said without disclosing any details on the changes to be made, the timeframe and the number of employees to be impacted.
Endpoints News first reported the development on Thursday.
Sanofi CEO Paul Hudson has been trying to build investor confidence in the company’s drug pipeline since he unexpectedly abandoned 2025 margin targets last October to instead boost drug development spending.
The company’s vaccine portfolio includes preventive shots for a common respiratory infection in infants, influenza vaccines, COVID vaccines and vaccines for infections like meningitis and tetanus.
(Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar)
Comments